19:51 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...
22:23 , Nov 1, 2018 |  BC Extra  |  Clinical News

BCMA race heats up as ASH abstracts released

Abstracts released ahead of next month's American Society of Hematology meeting highlighted the competition among products representing three anti-BCMA (TNF receptor superfamily member 17; TNFRSF17; CD269) modalities in development to treat multiple myeloma. On the...
00:48 , Oct 6, 2018 |  BioCentury  |  Finance

Seeking validation

The final stretch of the year offers clinical catalysts and early launch data that could validate investments in hot immuno-oncology targets and large untapped markets. Late-stage readouts from Vertex Pharmaceuticals Inc. in cystic fibrosis and...
06:14 , Aug 10, 2018 |  BC Week In Review  |  Company News

Regeneron, bluebird ink multitarget deal for cancer

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
22:43 , Aug 6, 2018 |  BC Extra  |  Company News

Regeneron, bluebird in multitarget cell therapy deal

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and bluebird bio Inc. (NASDAQ:BLUE) partnered to develop cell therapies against at least six undisclosed targets for cancer indications. The companies will use Regeneron's VelociSuite platform to discover and develop human...
05:42 , Jan 27, 2018 |  BioCentury  |  Strategy

Jump-starting growth

Celgene Corp.’s two deals this month -- including its largest ever acquisition, of Juno Therapeutics Inc. -- will help fill in the holes left by late-stage failures and commercial disappointments of candidates that were intended...
19:07 , Dec 8, 2017 |  BC Week In Review  |  Company News

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered on Dec. 7 to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC...
23:58 , Dec 7, 2017 |  BC Extra  |  Company News

bluebird, TC BioPharm in gamma delta CAR T deal

bluebird bio Inc. (NASDAQ:BLUE) and TC BioPharm Ltd. (Edinburgh, U.K.) partnered to discover and develop gamma delta chimeric antigen receptor (CAR) T cells to treat hematologic malignancies and solid tumors using TC BioPharm's ImmuniCAR technology....